Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-Lewis Y antibody
- Development stage
- Preclinical
- Lead developer
- GlycoNex
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
The anti-Lewis Y antibody is a protease-activated pro-antibody being co-developed by PrecisemAb Biotech and GlycoNex for the treatment of various cancers. It targets the Lewis Y (LeY) antigen, a carbohydrate glycan that is overexpressed on the surface of many epithelial tumors, including those of the breast, lung, colon, and ovary. The drug utilizes PrecisemAb's proprietary Universal Antibody Masking technology, which involves an inhibitory masking peptide linked to the antibody via a protease-cleavable sequence. This design ensures the antibody remains inactive in healthy tissues, reducing systemic toxicity, and is only activated within the tumor microenvironment where specific proteases are present to cleave the mask. Once activated, the antibody binds to Lewis Y on cancer cells to mediate anti-tumor effects, potentially through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
- Other names
- anti-LeY antibodyanti-Lewis Y pro-antibodyprotease-activated anti-Lewis Y antibody
02
Targets
Le^b (Lewis b antigen)LeY (Lewis Y antigen)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on anti-Lewis Y antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-Lewis Y antibody.